Bristol-Myers Squibb Continues to Lead the Advancement of Immuno-Oncology
Results for nivolumab and Yervoy® (ipilimumab) as a combination regimen in three tumor types to be presented, including melanoma and the first findings in non-small cell lung cancer and renal cell carcinoma.05/06/2014
Source: Kidney Cancer Association - Category: Cancer & Oncology Source Type: news
More News: Cancer | Cancer & Oncology | Carcinoma | Kidney Cancer | Lung Cancer | Melanoma | Non-Small Cell Lung Cancer | Renal Cell Carcinoma | Skin Cancer | Urology & Nephrology | Yervoy